Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;9 Suppl 1(Suppl 1):S3-8.

Androgen deprivation therapy in the treatment of advanced prostate cancer

Mark A Perlmutter  1 , Herbert Lepor
Affiliations

Androgen deprivation therapy in the treatment of advanced prostate cancer

Mark A Perlmutter et al. Rev Urol. 2007.

Abstract

This article reviews the issues and controversies relevant to the treatment of advanced prostate cancer with androgen deprivation therapy. Initially, diethylstilbestrol was used for achieving androgen deprivation, but was replaced by luteinizing hormone-releasing hormone (LHRH). Adverse events associated with LHRH agonists include the flare phenomenon, hot flashes, loss of libido, erectile dysfunction, depression, muscle wasting, anemia, and osteoporosis. Intermittent therapy has been advocated to reduce morbidity of treatment. The addition of an antiandrogen provides maximum androgen blockade. There remains controversy regarding the timing of the addition of an antiandrogen. Secondary hormonal therapies include antiandrogens, adrenal androgen inhibitors, and estrogens.

PubMed Disclaimer

References

    1. Huggins C, Hodges CV. Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209–223.
    1. Trachtenberg J. Hormonal management of stage D carcinoma of the prostate. In: Carson CC, editor. Problems in Urology. Vol. 7. Philadelphia: JB Lippincott Co; 1993. pp. 215–225.
    1. Roach M , 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911. - PubMed
    1. Ciezki JP, Klein EA, Angermeier K, et al. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys. 2004;60:1347–1350. - PubMed
    1. The Veterans Administration Co-Operative Urological Research Group, authors. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 1967;124:1011–1017. - PubMed

LinkOut - more resources